Biosimilar SB11 versus reference ranibizumab in neovascular age-related macular degeneration: 1-year phase III randomised clinical trial outcomes.
The British journal of ophthalmology（2023）
摘要
Longer-term results of this study further support the biosimilarity established between SB11 and RBZ.
更多查看译文
关键词
degeneration,macula,neovascularisation,retina
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要